Regeneron Pharmaceuticals, Inc. (REGN) delivered better-than-expected fourth-quarter 2023 results, despite declining sales of its lead drug, Eylea (aflibercept). Dupixent maintained its stellar performance, driven by continued strong demand in the approved indications, atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis and prurigo nodularis. The company reported fourth-quarter earnings per share of $11.86, which beat the Zacks Consensus Estimate of$10.43. The y ...